Tuesday, November 21, 2023
Viriom Inc. is excited to announce the successful completion of the Phase I clinical trial for AV5124, a revolutionary inhibitor of influenza virus replication. This new treatment demonstrates exceptional efficacy against various influenza types, even those resistant to neuraminidase inhibitors (such as Tamiflu®) and cap-dependent endonuclease inhibitors (like Zoflusa®).
The recently concluded Phase I clinical studies have revealed the outstanding safety and tolerability of AV5124. Furthermore, the blood drug levels achieved in the study indicate sustained virus suppression for several days following a single oral exposure. With its excellent safety profile and proven potency against influenza viruses, AV5124 is now set to progress into Phase II-III efficacy studies, scheduled to commence during this year's influenza season.
Laboratory studies supporting the development of AV5124 have demonstrated its remarkable ability to suppress Influenza A and Influenza B viruses, including drug-resistant variants. Notably, AV5124 also serves as a potent inhibitor of highly pathogenic avian influenza viruses found in nature, suggesting its potential application for seasonal or pandemic influenza treatment and preparedness. This significant advancement underscores Viriom's commitment to addressing the ever-changing challenges posed by influenza and other infectious or malignant diseases.